Literature DB >> 32635287

The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer.

Marta Hałas-Wiśniewska1, Wioletta Zielińska1, Magdalena Izdebska1, Alina Grzanka1.   

Abstract

BACKGROUND: Cancers are one of the leading causes of deaths nowadays. The development of new treatment schemes for oncological diseases is an interesting direction in experimental medicine. Therefore, the evaluation of the influence of two alkaloids-piperlongumine (PL), sanguinarine (SAN) and their combination-on the basic life processes of the A549 cell line was considered reasonable.
METHODS: The aim was achieved by analyzing the cytotoxic effects of PL and SAN and their combination in the ratio of 4:1 on the induction of cell death, changes in the distribution of cell cycle phases, reorganization of cytoskeleton and metastatic potential of A549 cells. The versatility of the applied concentration ratio was evaluated in terms of other cancer cell lines: MCF-7, H1299 and HepG2.
RESULTS: The results obtained from the MTT assay indicated that the interaction between the alkaloids depends on the concentration and type of cells. Additionally, the compounds and their combination did not exhibit a cytotoxic effect against normal cells. The combined effects of PL and SAN increased apoptosis and favored metastasis inhibition.
CONCLUSION: Selected alkaloids exhibit a cytotoxic effect on A549 cells. In turn, treatment with the combination of PL and SAN in a 4:1 ratio indicates a synergistic effect and is associated with an increase in the level of reactive oxygen species (ROS).

Entities:  

Keywords:  cell death; combination therapy; lung cancer; piperlongumine; sanguinarine

Year:  2020        PMID: 32635287     DOI: 10.3390/molecules25133045

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  3 in total

1.  Downregulation of FHOD1 Inhibits Metastatic Potential in A549 Cells.

Authors:  Marta Hałas-Wiśniewska; Magdalena Izdebska; Wioletta Zielińska; Alina Grzanka
Journal:  Cancer Manag Res       Date:  2021-01-08       Impact factor: 3.989

2.  Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity.

Authors:  Jie Shi; Yang Xia; Huihong Wang; Zhongjie Yi; Ruoruo Zhang; Xiufeng Zhang
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.810

Review 3.  The promising potential of piperlongumine as an emerging therapeutics for cancer.

Authors:  Dey Parama; Varsha Rana; Sosmitha Girisa; Elika Verma; Uzini Devi Daimary; Krishan Kumar Thakur; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.